Sleeping sickness treatment mystery unlocked

November 26, 2013, University of Dundee

(Medical Xpress)—Scientists at the Universities of Dundee and Glasgow have discovered how drugs that have been used for 60 years to kill the parasite that causes sleeping sickness actually work.

Research has revealed that the drugs used to attack Trypanosoma brucei enter through pores in the parasite's cells known as aquaporins which function as water channels.

It is the first time that drugs have been shown to enter cells through aquaporins and this may have major implications for drug delivery in other diseases.

Dr Harry de Koning, a Reader of Biochemical Parasitology at the University of Glasgow who has been studying drug resistance mechanisms in pathogenic protozoan parasites, said: 'This research is a breakthrough in understanding how the drugs used to attack the parasite get inside their target: like spies into an enemy castle they enter through a water channel.

'The discovery heralds a new paradigm for drug uptake by cells, as this is the first time that drugs have been shown to enter cells through aquaporins.

'Although there have been some reports of these channels being permeable to inorganic ions or small molecules, this is the first detailed report of an aquaporin acting as a genuine transport protein rather than a passive channel for mainly water.'

The Glasgow researchers, in collaboration with Professor David Horn of the University of Dundee, identified a genetic link between a single parasite gene and its susceptibility to the drugs pentamidine and melarsoprol, which were first introduced in the 1930s and 1940, respectively.

The gene in question coded for one of the trypanosome's channels for water and glycerol, aquaporin 2 (TbAQP2).

Aquaporins are found in virtually all organisms, from bacteria to humans, selectively mediating the uptake or release of water and/or glycerol, thus maintaining osmotic equilibrium.

At least thirteen different aquaporins are expressed in various human tissues, and hundreds of others have been identified in other species, comprising a large and highly conserved gene family. Their vital importance to life was recognised with a Nobel Prize, in 2003, to the discoverer of the first aquaporin gene.

The genome of Trypanosoma brucei, the protozoan parasite that causes African sleeping sickness, contains three such aquaporin genes, all of which appeared to be conventional water/glycerol channels.

The team at the University of Glasgow have now established that one of these channels, TbAQP2, uniquely, acts as a conduit for two drugs that are still essential for the treatment of sleeping sickness today.

They found mutations, rearrangements or loss of the TbAQP2 gene in every drug resistant strain that was examined, and were able to reverse this by introducing the original TbAQP2 gene back into these parasites.

Painstaking investigations into drug transport in parasites expressing original or mutant TbAQP2 channels showed that this protein actually also functions as a highly efficient transporter for pentamidine, used for the early stage of the disease, and melarsoprol, which is used for the late, cerebral stage.

Finally they showed that the introduction of TbAQP2 into a different parasite species, Leishmania mexicana, made those parasites more than 1000-fold more sensitive to melarsoprol.

Dr De Koning said, 'Although the phenomenon of melarsoprol/pentamidine cross-resistance was first described in 1951 it had never been satisfactorily explained. The current study, published in the Journal of Antimicrobial Chemotherapy, by identifying and characterising the melarsoprol/pentamidine transporter, finally resolves this vital issue.

'As virtually all living cells express aquaporins, this discovery has potentially far-reaching implications for cellular transport and permeation mechanisms, potentially impacting on our understanding of distribution in many different diseases.'

Explore further: Gene clue to drug resistance in African sleeping sickness

More information: Read the complete paper: … dkt442.full.pdf+html

Related Stories

Gene clue to drug resistance in African sleeping sickness

June 19, 2012
(Medical Xpress) -- Researchers have identified a gene that controls susceptibility to drug treatment in Trypanosoma brucei, the parasite responsible for African sleeping sickness.

New treatment for African sleeping sickness comes closer

November 6, 2013
Researchers at Umeå University have identified drugs targeting infections of the parasite Trypanosoma brucei and are thereby well on the way to find a cure against African sleeping sickness. This is the kernel of a thesis, ...

Major advance in sleeping sickness drug made by Glasgow scientists

September 6, 2011
A new study published in the open-access journal PLoS Neglected Tropical Diseases on September 6th presents a key advance in developing a safer cure for sleeping sickness. Led by Professor Peter Kennedy, researchers at the ...

Genetic technique brings new hope for better treatments for sleeping sickness

January 25, 2012
Research led by scientists at the London School of Hygiene & Tropical Medicine has exploited a revolutionary genetic technique to discover how human African Trypanosomiasis (HAT) drugs target the parasite which causes the ...

Scientists take a step towards better sleeping sickness treatment

April 25, 2012
(Medical Xpress) -- Scientists at the University of Glasgow have taken a major step forward in the quest to develop new, safer drugs for the treatment of sleeping sickness.

Recommended for you

Researchers illustrate how muscle growth inhibitor is activated, could aid in treating ALS

January 19, 2018
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for ...

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

Weight flux alters molecular profile, study finds

January 17, 2018
The human body undergoes dramatic changes during even short periods of weight gain and loss, according to a study led by researchers at the Stanford University School of Medicine.

Secrets of longevity protein revealed in new study

January 17, 2018
Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure ...

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Magnetically applied MicroRNAs could one day help relieve constipation

January 17, 2018
Constipation is an underestimated and debilitating medical issue related to the opioid epidemic. As a growing concern, researchers look to new tools to help patients with this side effect of opioid use and aging.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.